Navigation Links
Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel

Complements the RBM Rat Kidney Panel developed in conjunction with the Critical Path Initiative

AUSTIN, Texas, Jan. 15 /PRNewswire/ -- Rules-Based Medicine, Inc. (RBM), the world's leading multiplexed biomarker testing laboratory, today announced the launch of its Human Kidney Multi-Analyte Profile (MAP), a cost-effective biomarker testing service designed to aid pharmaceutical and biotechnology companies in their efforts to improve drug development through better understanding of drug toxicity. The Human Kidney MAP will be used in clinical trials to reveal early signs and locations of drug-induced kidney damage, known as renal toxicity or nephrotoxicity, thereby guiding important decisions on lead compounds and dosage.

"The Human Kidney MAP is an important response to the FDA's Critical Path Initiative, which highlighted the need for new tools to better understand the safety profile of new drugs," said Craig Benson, RBM president and chief executive officer. "By providing a quantitative and predictive multiplexed biomarker test for renal toxicity, we will help our customers improve safety, mitigate risk, and reduce costs associated with drug development."

RBM's Human Kidney MAP utilizes a multiplexed panel of 16 biomarkers to detect early renal damage and pinpoint the location within the kidney. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) recently decided to accept data related to certain biomarkers of kidney damage as part of the drug approval process in conjunction with new safety initiatives. Historically, regulatory agencies have required drug companies to provide results of blood urea nitrogen (BUN) and serum creatinine tests as indicators of kidney damage. Studies, however, suggest these tests detect only late signs of kidney damage and provide no information on the location of damage.

The Human Kidney MAP was developed using a translational medicine approach. In 2008, RBM commercialized a Rat Kidney MAP based on an ambitious study funded by the FDA's Critical Path Initiative through the Predictive Safety Testing Consortium. The Human Kidney MAP contains many of the same biomarkers and is designed to detect general signs of kidney damage. Drugs in circulation are concentrated up to 1000-fold in the kidney compared to plasma, magnifying the potential for renal toxicity of any drug.

Kidney damage also occurs in connection with diseases such as diabetes, hypertension, and autoimmune conditions, among others. RBM has established and is seeking additional collaborations with leading academic and pharmaceutical researchers to develop diagnostic applications based on the Human Kidney MAP.

About Rules-Based Medicine

Rules-Based Medicine (RBM) provides comprehensive protein biomarker products and services centered on its Multi-Analyte Profiling (MAP) technology. Its service platform (RodentMAP(R) and HumanMAP(R)) provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins cost-effectively in multiple species, and from a small sample volume. The Company also offers innovative and proprietary ex vivo testing systems such as TruCulture(TM), the first fully-closed, reproducible whole blood culture system. RBM is actively developing multiplexed diagnostic tests to detect the presence of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. More information about RBM is located at

RodentMAP(R) and HumanMAP(R) are registered trademarks of Rules-Based Medicine Inc.

SOURCE Rules-Based Medicine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
2. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
3. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
4. Novozymes Launches Enzyme to Reduce Acrylamide in Food
5. Enova Medical Launches Exos Corporation
6. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
7. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
8. ThirdBiotech Networking Group Launches
9. BioReliance Launches Next-Generation Genotoxicity Screening Service
10. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
11. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
Post Your Comments:
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership ... Professionals (OPBAP) has been formalized with the signing of a Memorandum of Understanding. ... OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
Breaking Biology News(10 mins):